Amarin (NASDAQ:AMRN) Posts Quarterly Earnings Results, Misses Estimates By $0.02 EPS

Amarin (NASDAQ:AMRN) posted its quarterly earnings results on Wednesday. The biopharmaceutical company reported ($0.06) EPS for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.02), Zacks reports. The firm had revenue of $42.30 million for the quarter, compared to the consensus estimate of $43.82 million. Amarin had a negative net margin of 16.33% and a negative return on equity of 7.15%. During the same quarter in the prior year, the company earned ($0.05) earnings per share.

Amarin Stock Up 1.1 %

Shares of NASDAQ:AMRN traded up $0.01 during midday trading on Friday, hitting $0.59. 803,613 shares of the stock traded hands, compared to its average volume of 1,547,164. The stock has a market capitalization of $240.73 million, a PE ratio of -6.51 and a beta of 1.92. Amarin has a one year low of $0.56 and a one year high of $1.37. The business’s 50 day moving average is $0.60 and its two-hundred day moving average is $0.71.

Amarin Company Profile

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.